Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 78 clinical trials
featured
CALGB 40903: A Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in Situ (DCIS)

CALGB 40903: A Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in Situ (DCIS)

  • 332 views
  • 08 Nov, 2020
  • 1 location
Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer

node positive breast cancer randomized between anastrozole/letrozole 5 years and anastrozole/letrozole 2-3 years switching to exemestane 3-2 years.

hormone therapy
invasive carcinoma
letrozole
estrogen
endocrine therapy
  • 0 views
  • 07 Nov, 2020
  • 1 location
Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE)

refining the understanding of the efficacy and safety of controlled ovarian stimulation with or without letrozole in young women with newly diagnosed breast cancer who are candidates to receive (neo

stage iv breast cancer
letrozole
adjuvant chemotherapy
breast carcinoma
cancer
  • 0 views
  • 23 Jan, 2021
  • 4 locations
Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole

used to increase stature: Anastrozole and Letrozole. It also should determine if there are differences in the side effect profiles of the two drugs to be used.

anastrozole
letrozole
aromatase inhibitor
serum luteinizing hormone
luteinizing hormone
  • 38 views
  • 08 Nov, 2020
  • 1 location
Ribociclib and Letrozole Treatment in Ovarian Cancer

The study evaluates the response to treatment with Ribociclib and Letrozole in patients with low grade serous cancer of the ovary, fallopian tube or peritoneum.

  • 26 views
  • 03 Feb, 2021
  • 26 locations
Palbociclib Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer

This study is investigating the combination of palbociclib, letrozole and venetoclax in ER and BCL-2 positive locally advanced or metastatic breast cancer. It is hypothesised that

measurable disease
metastatic carcinoma
palbociclib
mirena
neutrophil count
  • 45 views
  • 24 Jan, 2021
  • 3 locations
Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Phase II, randomized, open-label, international, multicenter study to compare efficacy of standard chemotherapy vs. letrozole plus abemaciclib as neoadjuvant therapy in HR-positive/HER2-negative

  • 0 views
  • 26 Jan, 2021
  • 28 locations
Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer

acquisition, study participants will take a 7- to 56-day (1-8 weeks) course of letrozole in accordance with standard of care. They will then undergo definitive surgical resection of their primary tumor

renal function
letrozole
breast carcinoma
measurable disease
raloxifene
  • 6 views
  • 25 Jan, 2021
  • 1 location
Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

The study is a prospective, single-arm, open label, exploratory phase 2 clinical trial, which aims to study the therapeutic effect of letrozole combined with anlotinib hydrochloride in platinum

  • 0 views
  • 28 Jan, 2021
  • 1 location
Exemestane Letrozole or Anastrozole in Treating Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer

are exemestane, anastrozole, letrozole. The purpose of this study is to find out whether it is better to receive exemestane, anastrozole, or letrozole to improve the chance that the

hormone therapy
exemestane
estrogen receptor
letrozole
anastrozole
  • 6 views
  • 07 Nov, 2020
  • 1 location